Clinical Trial Update: A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating CL-108 5 mg for acute pain and prevention of opioid-induced nausea/vomiting has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nausea
• Pain
• Vomiting

Drugs mentioned

• CL-108 (CL-108)

Snippet

Sponsor: Charleston Laboratories, Inc | Conditions: Pain, Nausea | Phase 3 | Status: COMPLETED | Results posted: 2023-03-22